Production (Stage)
EyePoint Pharmaceuticals, Inc.
EYPT
$9.03
$0.171.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -146.78M | -130.87M | -103.57M | -86.82M | -78.92M |
| Total Depreciation and Amortization | 1.73M | 1.54M | 1.19M | 892.00K | 662.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.84M | 30.88M | 27.85M | 25.87M | 22.64M |
| Change in Net Operating Assets | -27.97M | -27.77M | -38.95M | -29.60M | 43.15M |
| Cash from Operations | -148.18M | -126.23M | -113.49M | -89.66M | -12.46M |
| Capital Expenditure | -3.13M | -4.05M | -4.55M | -4.70M | -4.19M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -197.50M | -215.30M | -165.99M | -183.76M | -10.40M |
| Cash from Investing | -200.64M | -219.36M | -170.54M | -188.46M | -14.60M |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Debt Repaid | -140.00K | -105.00K | -73.00K | 0.00 | -35.31M |
| Issuance of Common Stock | 165.34M | 169.31M | 235.75M | 234.48M | 233.86M |
| Repurchase of Common Stock | -1.37M | -4.51M | -4.51M | -4.43M | -4.36M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -874.00K | -672.00K | -343.00K | -758.00K | -1.89M |
| Cash from Financing | 162.96M | 164.02M | 230.82M | 229.29M | 192.30M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -185.86M | -181.56M | -53.21M | -48.83M | 165.25M |